4.7 Article

Design, synthesis and anxiolytic-like activity of 1-arylpyrrolo[1,2-a]pyrazine-3-carboxamides

期刊

BIOORGANIC & MEDICINAL CHEMISTRY
卷 23, 期 13, 页码 3368-3378

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2015.04.049

关键词

Anxiolytic activity; Elevated plus maze test; Open field test; PK11195; Pyrrolo[1,2-a]pyrazines; TSPO; Vinyl azides

资金

  1. Basic Research Program of the Presidium of the Russian Academy of Sciences

向作者/读者索取更多资源

A series of 1-arylpyrrolo[1,2-a] pyrazine-3-carboxamides were designed and synthesized as 18 kDa translocator protein (TSPO) ligands. Anxiolytic-like activity of compounds was evaluated in the open field test and elevated plus maze test. Compounds 1a and 1b demonstrated high anxiolytic-like effect in the dose range of 0.1-1.0 mg/kg comparable with that of diazepam. The involvement of TSPO receptor in the mechanism of anxiolytic-like activity of new compounds was proved by antagonism of the most active compound 1a with TSPO selective inhibitor PK11195. In vitro binding studies demonstrated high TSPO affinities for compounds 1a and 1b. (C) 2015 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

Design, Synthesis, and Pharmacological Activity of New Pyrrolo[1,2-A]Pyrazine Translocator Protein (TSPO) Ligands

Grigory Mokrov, Andry Pantileev, Milada Yarkova, Tatiana Gudasheva, Sergei Seredenin

Summary: New TSPO ligands with high anxiolytic activity in the series of N,1-diphenylpyrrolo[1,2-a]pyrazine-3-carboxamides were successfully designed using calculated pharmacophore model and molecular docking analysis.

MEDICINAL CHEMISTRY (2022)

Review Chemistry, Medicinal

Linked biaromatic compounds as cardioprotective agents

Grigory V. Mokrov

Summary: Cardiovascular diseases are widespread and continue to grow in modern society, requiring the development of new safe drugs for treatment. Many cardioprotective agents adhere to a common pharmacophore model, suggesting the potential for designing new generation agents with multitarget mechanisms.

ARCHIV DER PHARMAZIE (2022)

Article Clinical Neurology

The neuropeptide cycloprolylglycine produces antidepressant-like effect and enhances BDNF gene expression in the mice cortex

Aliya A. Abdullina, Ekaterina V. Vasileva, Elizabeth A. Kulikova, Vladimir S. Naumenko, Alexandra Plyusnina, Tatyana A. Gudasheva, Georgy Kovalev, Sergei B. Seredenin

Summary: This study found that chronic CPG treatment is effective in reducing depressive-like behaviors, and the antidepressant-like effect is mediated, at least in part, by a BDNF-dependent mechanism. However, CPG does not negatively affect locomotor activity, cognition, or anxiety.

JOURNAL OF PSYCHOPHARMACOLOGY (2022)

Article Chemistry, Medicinal

Substituted Glyproline GZK-111 Retains Antihypoxic and Anxiolytic Activity Upon Peroral Administration

K. N. Kolyasnikova, P. Yu Povarnina, E. A. Kuznetsova, A. G. Alyaeva, T. A. Gudasheva, S. B. Seredenin

Summary: The substituted dipeptide GZK-111 retains its pharmacological effects, including antihypoxic and anxiolytic activities, after oral administration, which is important for its development as a potential drug for treating chronic diseases.

PHARMACEUTICAL CHEMISTRY JOURNAL (2022)

Article Chemistry, Medicinal

Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk

Armen G. Mezhlumyan, Anna Tallerova, Polina Y. Povarnina, Aleksey Tarasiuk, Nellya M. Sazonova, Tatiana A. Gudasheva, Sergey B. Seredenin

Summary: This study compares the antidepressant effects of different neurotrophin mimetics and identifies GSB-106 as the most promising candidate for developing antidepressant drugs.

PHARMACEUTICALS (2022)

Article Pharmacology & Pharmacy

Low molecular weight NGF mimetic GK-2 normalizes the parameters of glucose and lipid metabolism and exhibits a hepatoprotective effect on a prediabetes model in obese Wistar rats

Sergei Ivanov, Rita U. Ostrovskaya, Ksenia N. Koliasnikova, Irina B. Alchinova, Marina S. Demorzhi, Tatiana A. Gudasheva, Sergei B. Seredenin

Summary: This study models the signs of metabolic syndrome and prediabetes preceding type 2 diabetes using a high-fat diet (HFD). It investigates the effects of a low molecular weight nerve growth factor mimetic, GK-2, on indicators of abdominal obesity, blood glucose level, glucose tolerance, cholesterol and triglyceride levels, as well as the liver structure. The results show that GK-2 can reduce blood glucose, improve glucose tolerance, and lower cholesterol and triglyceride levels. It also mitigates abdominal obesity and eliminates liver abnormalities caused by the high-fat diet.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2022)

Article Pharmacology & Pharmacy

Chronically Administered BDNF Dipeptide Mimetic GSB-106 Prevents the Depressive-like Behavior and Memory Impairments after Transient Middle Cerebral Artery Occlusion in Rats

Polina Y. Y. Povarnina, Tatyana A. A. Antipova, Ilya O. O. Logvinov, Tatiana A. A. Gudasheva, Sergey B. B. Seredenin

Summary: The aim of this study was to investigate the effects of BDNF dipeptide mimetic GSB-106 on depressive-like behavior, cognitive impairments, and hippocampal neuroplasticity in an experimental model of ischemic stroke. The results showed that GSB-106 completely prevented behavior impairments and counteracted the reduction of immunoreactivity to CREB in the hippocampus. Therefore, the BDNF dipeptide mimetic GSB-106 holds promise for the treatment of poststroke neuropsychiatric disorders.

CURRENT PHARMACEUTICAL DESIGN (2023)

Review Biochemistry & Molecular Biology

Chaperone-Dependent Mechanisms as a Pharmacological Target for Neuroprotection

Mikhail V. Voronin, Elena V. Abramova, Ekaterina R. Verbovaya, Yulia V. Vakhitova, Sergei B. Seredenin

Summary: Modern pharmacotherapy of neurodegenerative diseases is primarily symptomatic and ineffective in halting disease progression. Protein misfolding is regarded as a crucial pathogenic factor in these diseases. Chaperones and endoplasmic reticulum stress mechanisms show promise in regulating these processes. This review provides an analysis of the role of BiP and Sigma1R chaperones in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease, and highlights the neuroprotective effect of Sigma1R ligand activation. The interaction between Sigma1R and BiP-associated signaling is also discussed, emphasizing the need for further study in this area.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Chemistry, Medicinal

Multitargeting in cardioprotection: An example of biaromatic compounds

Grigory V. Mokrov

Summary: A multitarget drug design approach is being developed in medicinal chemistry and pharmacology to target multifactorial diseases. This study focuses on the identification of basic pharmacophore models and the analysis of biological targets for cardioprotective drugs using the biaromatic pharmacophore as an example. It provides insights into the mechanisms of action of these drugs and their potential for treating cardiovascular diseases.

ARCHIV DER PHARMAZIE (2023)

Article Biochemistry & Molecular Biology

Pharmacological Analysis of GABAA Receptor and Sigma1R Chaperone Interaction: Research Report I?Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABAA Receptors' Ligands

Mikhail V. Voronin, Stanislav V. Shangin, Svetlana A. Litvinova, Elena V. Abramova, Rustam D. Kurbanov, Inna V. Rybina, Yulia V. Vakhitova, Sergei B. Seredenin

Summary: Previous drug development studies have established two groups of facts about the non-benzodiazepine anxiolytic fabomotizole. Firstly, it prevents the decrease in binding ability of the GABA(A) receptor's benzodiazepine site induced by stress. Secondly, it functions as a Sigma1R chaperone agonist, and its anxiolytic effect is blocked by Sigma1R antagonists. To investigate the involvement of Sigma1R in GABA(A) receptor-dependent pharmacological effects, various experiments were conducted on mice using Sigma1R ligands. The results show that Sigma1R antagonists attenuate while Sigma1R agonists enhance GABA(A) receptor-dependent pharmacological effects.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

暂无数据